GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mesoblast (MSB) shares

Learn how to easily invest in Mesoblast shares.

Mesoblast Limited is a biotechnology business based in Australia. Mesoblast shares (MSB) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Mesoblast employs 83 staff and has a trailing 12-month revenue of around AUDA$7.5 million.

How to buy shares in Mesoblast

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MSB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has Coronavirus impacted Mesoblast's stock price?

Since the stock market crash in March caused by coronavirus, Mesoblast's stock price has had significant negative movement.

Its last market close was A$1.6, which is 41.82% down on its pre-crash value of A$2.75 and 56.86% up on the lowest point reached during the March crash when the stocks fell as low as A$1.02.

If you had bought A$1,000 worth of Mesoblast stocks at the start of February 2020, those stocks would have been worth A$373.31 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth A$540.54.

Is it a good time to buy Mesoblast stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Mesoblast shares at a glance

Information last updated 2021-10-16.
Latest market closeA$1.60
52-week rangeA$1.50 - A$5.05
50-day moving average A$1.66
200-day moving average A$1.92
Wall St. target priceA$4.89
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) A$-0.22

Mesoblast stock price (Australian Securities Exchange (ASX): MSB)

Use our graph to track the performance of MSB stocks over time.

Mesoblast price performance over time

Historical closes compared with the close of A$1.6 from 2021-10-18

1 week (2021-10-11) 4.92%
1 month (2021-09-17) -2.44%
3 months (2021-07-17) -20.40%
6 months (2021-04-16) -31.03%
1 year (2020-10-16) -48.55%
2 years (2019-10-18) -9.09%
3 years (2018-10-18) 2.02
5 years (2016-10-18) 44.30%

Mesoblast financials

Revenue TTM A$7.5 million
Gross profit TTM A$-78,275,000
Return on assets TTM -9.22%
Return on equity TTM -17.48%
Profit margin 0%
Book value A$0.90
Market capitalisation A$1 billion

TTM: trailing 12 months

Mesoblast share dividends

We're not expecting Mesoblast to pay a dividend over the next 12 months.

Mesoblast share price volatility

Over the last 12 months, Mesoblast's shares have ranged in value from as little as A$1.5 up to A$5.05. A popular way to gauge a stock's volatility is its "beta".

MSB.AU volatility(beta: 2.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Mesoblast's is 2.4547. This would suggest that Mesoblast's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Mesoblast overview

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site